| Annual · values | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Cash Flow | -98276 USD | 6.67 M USD | 10.91 M USD | 621293 USD |
| Depreciation & Amortization | 141542 USD | 171346 USD | 151512 USD | 146658 USD |
| Stock-Based Compensation | 191565 USD | 224190 USD | — | — |
| Capital Expenditures | 65361 USD | 387876 USD | 134662 USD | 197802 USD |
| Cash Flow from Investing | -731031 USD | -225875 USD | -121162 USD | -197802 USD |
| Cash Flow from Financing | -3.59 M USD | 3.00 M USD | -10.97 M USD | -764374 USD |
| Dividends Paid | — | — | — | — |
| Stock Buybacks | — | — | — | — |
| Free Cash Flow | -163637 USD | 6.28 M USD | 10.78 M USD | 423491 USD |
Massimo Group Inc. is a leading company in the healthcare sector, primarily focusing on the development and production of innovative medical technologies. The company's core purpose is to enhance patient care by providing high-performance diagnostic and therapeutic solutions. Massimo Group Inc. is renowned for its cutting-edge advancements in non-invasive monitoring technologies, which play a crucial role in hospitals, clinics, and medical facilities worldwide. Products such as vital sign monitors and pulse oximeters are integral to its portfolio, contributing significantly to patient health and safety. The company engages with a wide array of healthcare professionals, including clinicians and emergency medical staff, supporting their operations with reliable and efficient equipment. As a critical player in the medical technology industry, Massimo Group Inc. is pivotal in driving improvements in healthcare delivery, emphasizing both accuracy and accessibility. With its commitment to continuous research and development, Massimo Group Inc. not only maintains a competitive edge but also upholds its position as a vital entity in the healthcare technology market.